June 16-19, 2025

Boston Convention & Exhibition Center

Menu

2025 Program

At BIO 2025, the world can’t wait for experts across the industry to share critical insights on ground-breaking therapies and innovation. During the 135+ sessions in our program you’ll hear from leading biotechnology companies, investors, service providers, government officials, regulators, and patient advocates across 18 different focus areas, including AI and digital health, next generation biotherapeutics, business development and more.

 

Use the Favorites feature ❤ to choose programs you're interested in and then click on the number of Favorites to generate a PDF of your selected sessions.
My favorites:      

Wishlist

Add some favourites to your wishlist to get started!

Loading
Search Filters
  • Date
  • Focus Area
  • Session Type
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
11:00 AM – 12:00 PM
(ET)
  1. Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
    Breakout Session
    • AI and Digital Health
    Moderator
    Josh Seidenfeld
    Josh Seidenfeld, Partner - Cooley LLP
12:00 PM – 1:00 PM
(ET)
  1. AI in Biologics Drug Discovery: Analyzing the Competitive Landscape, Technical Approaches, and the Industry's Role
    Breakout Session
    • AI and Digital Health
    Moderator
    Darren Platt
    Darren Platt, Chief Data Officer - Montage Bio
    Speakers
    Jiye Shi
    Jiye Shi, Vice President, Discovery Chemistry Research and Technologies - Eli Lilly and Company
    Alex Lugovskoy
    Alex Lugovskoy, CEO and Co-founder - Diagonal Therapeutics Inc
    Alex Morgan
    Alex Morgan, Partner - Khosla Ventures
    Georgia Lu
    Georgia Lu, Managing Partner - Magnet Ventures
    Chelsea Sumner
    Chelsea Sumner, NALA Healthcare AI Startups Lead - NVIDIA
1:45 PM – 5:15 PM
(ET)
  1. Oncology Investment Themes: Where is the Market Putting its Money?
    Breakout Session
    • Oncology
    Moderator
    Ashwin Singhania
    Ashwin Singhania, Partner - Ernst & Young
    Speakers
    Jack Wu
    Jack Wu, Senior Director, Search & Evaluation, Global Oncology - Takeda
    Liz Barrett
    Liz Barrett, CEO - Urogen
    Christopher Mortko
    Christopher Mortko, Vice President, Business Development & Licensing - Merck
    Dan Switzer
    Dan Switzer, Head of US Oncology Business Division - Daiichi Sankyo
  2. Leveraging the Accelerated Approval Pathway for Rare Diseases
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Heather McKenzie
    Heather McKenzie, Senior Editor - BioSpace
    Speakers
    Emil Kakkis
    Emil Kakkis, President and CEO - Ultragenyx
    Joseph Ross
    Joseph Ross, Professor of Medicine and Public Health - Yale School of Medicine
    Neil McFarlane
    Neil McFarlane, Chief Executive Officer - Zevra Therapeutics
    Camille Bedrosian
    Camille Bedrosian, Chief Medical Officer - Amylyx Pharmaceuticals, Inc.
  3. AI in Biopharma: What’s Working and What’s Left to Prove
    Breakout Session
    • AI and Digital Health
    Moderator
    Megan Nacar
    Megan Nacar
    Speakers
    Rafael Rosengarten
    Rafael Rosengarten, Chief Executive Officer and Co-founder - Genialis
    Attila Csikasz-Nagy
    Attila Csikasz-Nagy, CEO - Cytocast
    Maria Luisa Pineda
    Maria Luisa Pineda, Co-founder & CEO - Envisagenics
    Jason Raeburn
    Jason Raeburn, Partner, Judge, Deputy Master of the High Court - Paul Hastings
    Alex Zhavoronkov
    Alex Zhavoronkov, CEO & Founder - Insilico Medicine
  4. Preparing for the Next Generation in Antimicrobial Resistance: Combining Traditional with Non-Traditional Therapeutic Approaches to Tackle an Ongoing Pandemic
    Breakout Session
    • Infectious Disease and Vaccines
    Moderator
    Steve St Onge
    Steve St Onge, Senior Vice President of Corporate Development - Clarametyx Biosciences
    Speakers
    Erin Duffy
    Erin Duffy, Chief of Research and Development - CARB-X
    Judith Steenbergen
    Judith Steenbergen, Chief Executive Officer - Scientific and Medical Affairs Consulting
    Maud Eijkenboom
    Maud Eijkenboom, Managing Director - Lixa Pty Ltd
    Steve Sandor
    Steve Sandor, VP, Market Access, Trade and Government Affairs - Paratek Pharmaceuticals
    Ella Balasa
    Ella Balasa, Patient Advocate and Advisor - Balasa Consulting
  5. Beyond Innovation: Supercharging America's Biomanufacturing Infrastructure
    Breakout Session
    • Biomanufacturing
    Moderator
    Vic Suarez
    Vic Suarez, Founder & Principal Growth Partner - Blu Zone Bioscience & Supply Chain Solutions
    Speakers
    Katherine Sixt
    Katherine Sixt, Principal Director for Biotechnology in the Office of the Under Secretary of Defense for Research and Engineering - US Department of Defense
    Tim Belski
    Tim Belski, Program Director - Biopharmaceutical Manufacturing Preparedness (BioMaP) DHHS/ASPR/BARDA
    Paul Hill
    Paul Hill, SVP, Process Development & Engineering - Amyris
    Aji Parayil
    Aji Parayil, Founder & CEO - Manus
    Phil Trump
    Phil Trump, Chief Science and Technology Officer - Danimer Scientific
  6. Effective Use of the New European Patent System as Part of Your Global Patent Strategy
    Breakout Session
    • Intellectual Property and Legal Landscape
    Moderator
    Robert Alderson
    Robert Alderson, Partner - United States and European Patent Attorney - Berggren Oy
    Speakers
    Jennifer Burdman
    Jennifer Burdman, Intellectual Property Strategist and Advisor - Sauvegarder Investment Management
    Alfonso Chan
    Alfonso Chan, Partner - King & Spalding
    Arno Risse
    Arno Risse, Partner at ARNOLD RUESS - ARNOLD RUESS
  7. Shaping Strategies for Impact, Resilience and Lasting Value
    Breakout Session
    • Environmental Sustainability
    Moderator
    Sharon Gordon
    Sharon Gordon, Head of Social Impact Team, Corporate Affairs Practice - Syneos Health
  8. Psychedelics Are Going Mainstream. Are You Ready For It?
    Breakout Session
    • Brain Health
    Moderator
    Drew Levinson
    Drew Levinson, Executive Vice President, Head of Media Relations - LifeSci Communications
    Speakers
    Daniel Karlin
    Daniel Karlin, Chief Medical Officer - MindMed
    Michael Kobernick, MD
    Michael Kobernick, MD, Senior Medical Director - Blue Cross Blue Sheild of Michigan
    Katie Walker
    Katie Walker, Patient Advocate; Licensed Certified Social Worker, Registered Play Therapist - Patient; Indigo Counseling
    Sharmin Ghaznavi, MD, PhD
    Sharmin Ghaznavi, MD, PhD, Associate Director, Center for the Neuroscience of Psychedelics - Massachusetts General Hospital; Harvard Medical School
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
  9. From Skepticism to Opportunity: Building Investor Confidence in First-in-Class and First-in-Disease Drug Innovation
    Breakout Session
    • Business Development and Investment
    Moderator
    Alan Crane
    Alan Crane, Entrepreneur Partner - Polaris Partners
    Speakers
    Kathy Dong
    Kathy Dong, President and Chief Executive Officer - Electra Therapeutics
    Rajiv Patni
    Rajiv Patni, CEO - Judo Bio
    Jo Viney
    Jo Viney, Founder, President and Chief Executive Officer - Seismic Therapeutic
    Marc Schwabish
    Marc Schwabish, Chief Business Officer - Tectonic Therapeutic
  10. Who Are Today’s Biotech Underdogs and What Will It Take for Them to Succeed?
    Breakout Session
    • Business Development and Investment
    Moderator
    Max Bayer
    Max Bayer, Pharma Reporter - Endpoints News
    Speakers
    Deborah Baron
    Deborah Baron, Senior Vice President, Worldwide Business Development - Pfizer
    Jeffrey Meckler
    Jeffrey Meckler, CEO - Indaptus Therapeutics
    Matt Gline
    Matt Gline, Chief Executive Officer - Roivant Sciences
    Steven Damon
    Steven Damon, CEO - Micron Biomedical, Inc.
    Tim Opler
    Tim Opler, Managing Director - Stifel
  11. Augmented Medicines: Use XR Headsets to See What Patients See (Try-It-Yourself Demos)
    Special Program
    • AI and Digital Health
3:00 PM – 4:00 PM
(ET)
  1. We’ve Entered a New Era of Neuropsychiatry: Precision in Practice
    Breakout Session
    • Brain Health
    Moderator
    Rowan Walrath
    Rowan Walrath, Associate Editor - Chemical & Engineering News
    Speakers
    Jacob Donoghue
    Jacob Donoghue, CEO & Co-Founder - Beacon Biosignals
    Katherine Burdick
    Katherine Burdick, Professor of Psychology, Department of Psychiatry, Brigham and Women's Hospital - Harvard Medical School
    Patricio O’Donnell
    Patricio O’Donnell, VP, Translational Medicine - Alto Neuroscience
  2. Journey Into the [Un]validated – A Practical Guide to Partnering Early with Pharma on Novel Drug Modalities
    Breakout Session
    • Business Development and Investment
    Moderator
    Amanda Kay
    Amanda Kay, Senior Partner, Chief Business Development Officer - Flagship Pioneering
    Speakers
    Barbara Lueckel
    Barbara Lueckel, Global Head of Research Technologies - Roche
    Michael Palladinetti
    Michael Palladinetti, Global Head of Business Development & Licensing - Sanofi
    Svetlana Lucas
    Svetlana Lucas, Chief Business Officer - Scribe Therapeutics
  3. Best Practice for Genuine Sustainability from Pharmaceutical Companies in Latin America
    Breakout Session
    • Environmental Sustainability
    Moderator
    Angelica Navarro
    Angelica Navarro, Partner - Baker McKenzie
    Speakers
    Beatriz Veiga Carvalho
    Beatriz Veiga Carvalho, AGC - Growth and Emerging Markets - Baxter International Inc
    Laura Jaramillo Franco
    Laura Jaramillo Franco, Head of Law, Patents and Compliance. Andean, Central America and Caribbean - Bayer
  4. How to Best Scale CGT Manufacturing: Bringing Together Disparate Approaches
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Jef Akst
    Jef Akst, Managing Editor - BioSpace
    Speakers
    Courtney Rice
    Courtney Rice, Principal - Acadia Strategy Partners
    Jason Foster
    Jason Foster, Chief Executive Officer - Ori Biotech
    Michael Paglia
    Michael Paglia, Chief Technology Officer - ElevateBio
    Josh Ludwig
    Josh Ludwig, Global Director Commercial Operations - Wilson Wolf
    Joanne Beck
    Joanne Beck, Chief Technical Officer - Abata Therapeutics
  5. Rapid Response Capabilities of Global Health and Biosecurity Countermeasures During Outbreaks - Leveraging Public Private Partnerships
    Breakout Session
    • Infectious Disease and Vaccines
    Moderator
    Emma Wheatley
    Emma Wheatley, Executive Director Access and Business Development - CEPI
    Speakers
    Holger Kissel
    Holger Kissel, SVP, Scientific Relations & Liaison - BioNTech
    Vicky Leamy
    Vicky Leamy, Vice President, Therapeutic Science and Strategy - IQVIA
    Amy Finan
    Amy Finan, CEO - Sabin Vaccine Institute
  6. European Biotech: Unlocking Investment Opportunities
    Breakout Session
    • Business Development and Investment
    Speakers
    Jérôme Van Biervliet
    Jérôme Van Biervliet, Managing Director - VIB
    Matthew Foy
    Matthew Foy, CEO & Managing Partner - SR One
    Renée Lucander
    Renée Lucander, CEO - Calliditas
    Christina Takke
    Christina Takke, Managing Partner - V-Bio Ventures
  7. Understanding and Mitigating the Consequences of Loper Bright, Corner Post & Judicial Activities on Drug Development, Commercialization, and Investment
    Breakout Session
    • Intellectual Property and Legal Landscape
    Moderator
    Lori Ellis
    Lori Ellis, Head of Insights - BioSpace
    Speakers
    Chris Hart
    Chris Hart, Partner - Foley Hoag
    Konstantina Katcheves
    Konstantina Katcheves, Senior Vice President, Innovative Medicines Business Development - Teva Pharmaceuticals
    Edie Stringfellow
    Edie Stringfellow, SVP, Global Health Strategy and Biomedical Commercialization - Precia Group
    Michelle Longmire
    Michelle Longmire, CEO & Co-founder - Medable
  8. Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
    Breakout Session
    • Biomanufacturing
    Moderator
    Uduak Thomas
    Uduak Thomas, Senior Editor - Genetic Engineering & Biotechnology News
    Speakers
    Lee Cronin
    Lee Cronin, Chief Executive Officer and Chief Scientific Officer - Chemify
    Raphael Townshend
    Raphael Townshend, Founder and Chief Executive Officer - Atomic AI
    Daniel Kuhn
    Daniel Kuhn, Director, Head of AI and Computational Technologies - Merck Group
  9. Preparing for an IPO: Best Practices for Success
    Breakout Session
    • Business Development and Investment
    Moderator
    Kimberly Ha
    Kimberly Ha, CEO - KKH Advisors
    Speakers
    Jennifer Fang
    Jennifer Fang, Partner - Wilson Sonsini
    Andrew Lam
    Andrew Lam, Managing Director, Head of Biotech Private Equity - Ally Bridge Group
    Chirag Surti
    Chirag Surti, Executive Director, Global Capital Markets - Morgan Stanley
    Jordan Saxe
    Jordan Saxe, Head of Healthcare Listings - NASDAQ
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
4:15 PM – 5:15 PM
(ET)
  1. Translating Nobel Prize Science into the Clinic
    Breakout Session
    • Translational Research
    Moderator
    Barbara Cheifet
    Barbara Cheifet, Chief Editor - Nature Biotechnology
    Speakers
    Sharon Rosenzweig-Lipson
    Sharon Rosenzweig-Lipson, Chief Scientific Officer - Life Biosciences
    Michael Severino
    Michael Severino, Chief Executive Officer - Tessera Therapeutics
    Eamonn Hobbs
    Eamonn Hobbs, President and Chief Executive Officer - Syncromune
    John Lepore
    John Lepore, Chief Executive Officer - ProFound Therapeutics
  2. Foundation Models for Genomics: Current Advances and Future Directions
    Breakout Session
    • AI and Digital Health
    Moderator
    Martin Gershon
    Martin Gershon, Managing Partner & Chief Strategy Officer, Endeavor Venture Group - Senior Lead Mentor-in-Residence Techstars, Advisor White House CancerX Moonshot Accelerator
    Speakers
    Thomas Pierrot
    Thomas Pierrot, Staff Research Scientist - InstaDeep
    Vikram Agarwal
    Vikram Agarwal, Head of mRNA Platform Design Data Science, mRNA Center of Excellence - Sanofi
    Tommaso Biancalani
    Tommaso Biancalani, Senior Director and Head of AI for Research Biology - Genentech
    Maximilian Lombardo
    Maximilian Lombardo, Product Manager - Chan Zuckerberg Initiative
    Peter Koo
    Peter Koo, Associate Professor - Cold Spring Harbor Laboratory
  3. The Priority Review Voucher Program: Incentivizing Neglected Disease Research and Promoting Biotech Investment and Development for More than a Decade
    Breakout Session
    • Business Development and Investment
    Moderator
    Edward Diehl
    Edward Diehl, Commercialization Officer - Defense Health Agency
    Speakers
    Steven Ferguson
    Steven Ferguson, Special Advisor, NIH Office of Technology Transfer - National Institutes of Health
    David Ridley
    David Ridley, Faculty Director for the Center for Health Sector Management - Duke University
    Barry Datlof
    Barry Datlof, Chief, Business Development and Commercialization - Defense Health Agency
    Joe Zenkus
    Joe Zenkus, Senior VP, Corporate Development, Strategy & Alliances - Sarepta
  4. Platform Licensing: Biotech and Pharma Perspectives
    Breakout Session
    • Business Development and Investment
    Moderator
    Oren Livne
    Oren Livne, Partner - Baker McKenzie
    Speakers
    Casarine Chong
    Casarine Chong, Senior Vice President, Deputy General Counsel, Transactions - Bristol Myers Squibb
    Gavin Liu
    Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas
    Deepa Talpade
    Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
    Maria Nichol
    Maria Nichol, Chief Business Officer - Artax Biopharma
    Ellen Lubman
    Ellen Lubman, Advisor - Werewolf Therapeutics
  5. Profit and Access: Groundbreaking Strategies to Make Medicines Available in Resource-Challenged Markets
    Breakout Session
    • Emerging Opportunities in Global Markets
    Moderator
    Jeffrey Sturchio
    Jeffrey Sturchio, Chair - Friends of the Global Fight Against AIDS, Tuberculosis and Malaria
    Speakers
    Clifford Samuel
    Clifford Samuel, Principal - PCMS1 Consulting
    Aparna Parikh
    Aparna Parikh, Associate Professor of Medicine and Director MGH Cancer Center Global Cancer Care Program - Harvard Medical School and Massachusetts General Hospital
    Michael Chu
    Michael Chu
    Muz Mansuri
    Muz Mansuri
  6. It’s Not “Just the Flu”: Harnessing Innovation to Save Lives
    Breakout Session
    • Infectious Disease and Vaccines
    Moderator
    Niki Carelli
    Niki Carelli, Senior Vice President, The Daschle Group - Executive Director, Coalition To Stop Flu
    Speakers
    Jacob Glanville
    Jacob Glanville, CEO - Centivax
    Marcus Lacey
    Marcus Lacey, Executive Director - Global Pandemic Head - CSL Seqirus
    Ken Kelley
    Ken Kelley, CEO - IDBiologics, Inc.
    Hassan Zaraket
    Hassan Zaraket, Global Medical Science Leader, Infectious Diseases - Roche
  7. Examining Innovative Business Models for Creating Sustainable Network and Capabilities for Public Health and Biosecurity Countermeasures
    Breakout Session
    • Business Development and Investment
    Moderator
    Emma Wheatley
    Emma Wheatley, Executive Director Access and Business Development - CEPI
    Speakers
    Derrick Sim
    Derrick Sim, Interim Chief Vaccine Programs and Markets Officer - GAVI The Vaccine Alliance
    Rajinder Kumar Suri
    Rajinder Kumar Suri, CEO - Developing Countries Vaccine Manufacturers Network (DCVMN) International
  8. Intellectual Property Considerations for Inventions Made By, Or Involving, Artificial Intelligence
    Breakout Session
    • Intellectual Property and Legal Landscape
    Moderator
    John Storella
    John Storella, Partner - Storella & Witt
    Speakers
    Madhuri Roy
    Madhuri Roy, Partner - Cooley, LLP
    Ali Alemozafar
    Ali Alemozafar, Partner - Wilson Sonsini Goodrich & Rosati
    Marc Wilkinson
    Marc Wilkinson, Partner - J A Kemp LLP
    Amy Feng
    Amy Feng, Partner and Co-founder - Wu, Feng & Zhang
    Zhen Zhang
    Zhen Zhang
  9. Beyond the Contract: Building Successful Biotech Partnerships
    Breakout Session
    • Biomanufacturing
    Moderator
    Tyler Menichiello
    Tyler Menichiello, Chief Editor - Bioprocess Online
    Speakers
    Eric Cunningham
    Eric Cunningham, VP, CMC & Process Development - Sequoia Vaccines
    Elliott Franco
    Elliott Franco, Vice President, Laboratory Operations - Alcami
    Jessica Blomberg
    Jessica Blomberg, Founder & CEO - Quality CMC Consulting
    Rose Rhomberg
    Rose Rhomberg, Senior Director, Sales and Business Development - Cytovance Biologics
    Jim Beach
    Jim Beach, CEO - Bexion Pharmaceuticals
  10. Next-Generation Alzheimer's Disease Therapies
    Breakout Session
    • Brain Health
    Moderator
    Phyllis Ferrell
    Phyllis Ferrell, Chief Impact Officer - Alzheimer’s Moonshot - Startup Health
    Speakers
    Maha Radhakrishnan
    Maha Radhakrishnan, Executive Partner, Private Equity - Sofinnova Investments
    Beth Hoffman
    Beth Hoffman, CEO - Origami Therapeutics
    Christian Howell
    Christian Howell, CEO - Cognito Therapeutics
    Mike Zuendel
    Mike Zuendel, Founder and Advocate-in-Chief - Initiative to Change the "D-Word"
11:00 AM – 12:00 PM
(ET)
  1. Patient Diversity and Access to New Medicines – Can AI Improve Access in Disadvantaged Patient Populations and Optimize the Economics of Medical Innovation?
    Breakout Session
    • AI and Digital Health
    Moderator
    Drew Cutshaw
    Drew Cutshaw, Principal - Pappas Capital
    Speakers
    Murray Aitken
    Murray Aitken, Executive Director - IQVIA Institute for Human Data Science
    Marianne Hamilton Lopez
    Marianne Hamilton Lopez, Senior Research Director of Biomedical Innovation - Duke Margolis Institute for Health Policy
    William Crown
    William Crown, Distinguished Research Scientist - Heller School for Social Policy and Management
    Xavior Robinson
    Xavior Robinson, Director Health Equity Partnerships and Operations - Merck
  2. From Discovery to Deals: Bridging the Valley-of-Death with a Molecule-to-Medicine Expressway
    Breakout Session
    • Oncology
    Moderator
    Karim Budhwani
    Karim Budhwani, CEO-Scientist - CerFlux
    Speakers
    Kara Bortone
    Kara Bortone, Senior Director, J&J Innovative Medicine Business Development - Johnson & Johnson
    Sandeep Menon
    Sandeep Menon, Chief Development Officer, Head of Development and Safety - Alnylam
    Maggie Scully
    Maggie Scully, Partnership Development Director - Frederick National Laboratory for Cancer Research
    Christopher Mortko
    Christopher Mortko, Vice President, Business Development & Licensing - Merck
  3. Shifting Attitudes Toward Vaccines Among Lawmakers
    Breakout Session
    • Infectious Disease and Vaccines
    Moderator
    Phyllis Arthur
    Phyllis Arthur, Executive Vice President & Head of Healthcare Policy and Programs - Biotechnology Innovation Organization (BIO)
    Speakers
    Sherri Berger
    Sherri Berger, Founder and CEO - SB Strategies
    Luciana Borio
    Luciana Borio, Senior Fellow for Global Health - Council on Foreign Relations
    Amanda Cohn
    Amanda Cohn, Head, North America Medical, New Products - Sanofi
    Catherine O’Neal
    Catherine O’Neal, Chief Academic Officer - Franciscan Missionaries of Our Lady Health System in Louisiana
    Larry Bucshon
    Larry Bucshon, Senior Policy Advisor and Former Member of Congress - Holland and Knight LLP
  4. Navigating Regulations to Bring Cell/Gene Therapies to Patients in Europe and Middle East
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Els Janssens
    Els Janssens, Counsel - Baker McKenzie
    Speakers
    Georgia Gavriilidou
    Georgia Gavriilidou, Head of Legal Department - European Medicines Agency
    Arianna Greco
    Arianna Greco, SVP, General Counsel Commercial - Alnylam Pharmaceuticals
    Laura Liebers
    Laura Liebers, Director, Head of Global Regulatory Intelligence - Vertex Pharmaceuticals
    Hashmi Shahrukh
    Hashmi Shahrukh, Director of Research, Professor of Medicine - Department of Health Abu Dhabi; Mayo Clinic, Rochester, Minnesota, United States
  5. Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today
    Breakout Session
    • Biomanufacturing
    Moderator
    Abhijit Kulkarni
    Abhijit Kulkarni, Chief Operating Officer - Cellino Biotech
    Speakers
    Alexis Rovner
    Alexis Rovner, CEO & Founder - 64x Bio
    Mohit Trikha
    Mohit Trikha, President & COO - Kivu Bioscience
    Bruna Paulsen
    Bruna Paulsen, VP, Manufacturing and Therapeutic Development - Gameto
    Jennifer Lum
    Jennifer Lum, Managing Partner - Biospring
    Kate Rochlin
    Kate Rochlin, Chief Operating Officer - IN8bio
  6. Advancing Innovative Risk-Stratification Tests that Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry
    Breakout Session
    • Diagnostics and Personalized Medicine
    Moderator
    Michael Ryan
    Michael Ryan, Partner - McDermott Will & Emery
    Speakers
    Derek Maetzold
    Derek Maetzold, Founder, President and CEO - Castle Biosciences
    Robin Cowie
    Robin Cowie, Chief Financial Officer - Biodesix
    Kimberly Linthicum
    Kimberly Linthicum, Principal - Todd Strategy Group
    Gillian Hooker
    Gillian Hooker, Chief Scientific Officer - Concert
    Mara Aspinall
    Mara Aspinall, Partner - Illumina Ventures
  7. How VCs Evaluate Risk in Early Stage Startups
    Breakout Session
    • Business Development and Investment
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Kouki Harasaki
    Kouki Harasaki, Founding / Managing Partner - Bioluminescence Ventures
    Rebecca Silberman
    Rebecca Silberman, Investment Director - RA Capital Management
    Jernej Godec
    Jernej Godec, Principal - Atlas Venture
  8. Patient-Reported Outcomes are Front and Center for Drug Development AND with the FDA and the CDC
    Breakout Session
    • Regulatory Innovation
    Moderator
    Mary Beth Cicero
    Mary Beth Cicero, Founder & CEO - 3Daughters, Inc.
    Speakers
    Nancy Kivel
    Nancy Kivel, Senior Vice President, Global Health General Medicine, and Section Head Women's Health - Parexel International
    Aaron Lazorwitz
    Aaron Lazorwitz, Assistant Professor, Div. of Complex Family Planning & Reproductive Sciences - Yale University School of Medicine
  9. Economic Development Policy and Partnerships in Biomanufacturing: State and Regional Perspectives
    Special Program
1:45 PM – 2:45 PM
(ET)
  1. Next-Gen Advocates: Patients & Families Driving Breakthroughs in Rare Disease Drug Development
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    Lei Lei Wu
    Lei Lei Wu, Reporter - Endpoints News
    Speakers
    Michelle Werner
    Michelle Werner, CEO / CEO-Partner - Alltrna / Flagship Pioneering
    Julia Vitarello
    Julia Vitarello, Co-founder - EveryONE Medicines
    Jill Chertow
    Jill Chertow, Founder and President - Propionic Acidemia Foundation
    Wendy Erler
    Wendy Erler
    Karin Knobe
    Karin Knobe
  2. Undermining Innovation: How Antimicrobial Resistance Imperils Patients and Threatens the Future of Medicine
    Breakout Session
    • Infectious Disease and Vaccines
    Moderator
    Henry Skinner
    Henry Skinner, Chief Executive Officer - AMR Action Fund
    Speakers
    Kieren Marr
    Kieren Marr, President and Chief Medical Officer - Elion Therapeutics, Inc.
    Christina Yen
    Christina Yen, Infectious diseases specialist and medical director of antimicrobial stewardship - MaineHealth Maine Medical Center
    Ellen Fraint
    Ellen Fraint, Attending, Pediatric Transplantation and Cellular Therapy - Nemours Children's Health / Nemours Children's Hospital
  3. Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks
    Breakout Session
    • AI and Digital Health
    Moderator
    Rory Kelleher
    Rory Kelleher, Senior Director, Global Head of Business Development, Healthcare and Life Sciences - NVIDIA
    Speakers
    Gregg Talbert
    Gregg Talbert, Senior Vice President, Head of Pharma Transactions and Digital Partnering - Genentech
    Najat Khan
    Najat Khan, Chief R&D Officer and Chief Commercial Officer - Recursion
    Karen Akinsanya
    Karen Akinsanya, President, R&D - Therapeutics - Schrödinger
    Martha Head
    Martha Head, Associate Vice President of the Center for Research Acceleration by Digital Innovation - Amgen
    Derek Lowe
    Derek Lowe, Director in Chemical Biology & Therapeutics - Novartis
  4. Global Puzzle: Decoding Cell Therapy Classifications in Europe and the USA
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Jasmina Savic
    Jasmina Savic, Managing Director - Phortas GmbH
    Speakers
    Jasmina Savic
    Jasmina Savic, Managing Director - Phortas GmbH
    Eveline Van Keymeulen
    Eveline Van Keymeulen, Partner and Global Vice Chair of the Life Sciences Practice - LATHAM & WATKINS
  5. Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled
    Breakout Session
    • Business Development and Investment
    Moderator
    Hannah Green
    Hannah Green, Life Sciences Reporter - Boston Business Journal
    Speakers
    Uli Stilz
    Uli Stilz, Head of the Bio Innovation Hub - Novo Nordisk
    Paul Biondi
    Paul Biondi, General Partner; President - Flagship Pioneering; Pioneering Medicines
    Ram Aiyar
    Ram Aiyar, Chief Executive Officer and President - Korro Bio, Inc.
    Lovisa Afzelius
    Lovisa Afzelius, General Partner; Co-Founder and Founding CEO - Flagship Pioneering; Metaphore Biotechnologies
  6. Attacking Cancer from All Angles: From ADCs to Immunotherapy
    Breakout Session
    • Oncology
    Speakers
    Raquel Izumi
    Raquel Izumi, President and Chief Operating Officer - Vincerx Pharma
    Biljana Naumovic
    Biljana Naumovic, Worldwide Vice President, Global Commercial Strategy Oncology - Johnson & Johnson Innovative Medicine
    George Eliades
    George Eliades, CEO - Mythic Therapeutics, Inc.
  7. Improving and Restoring Vision in Blinding Eye Diseases
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Jason Menzo
    Jason Menzo, CEO - Foundation for Fighting Blindness
    Speakers
    Fred Guerard
    Fred Guerard, CEO - Opthea
    Greg Kunst
    Greg Kunst, CEO - Aurion Biotech
    Paul Bresge
    Paul Bresge, CEO - Ray Therapeutics
    Sulagna Bhattacharya
    Sulagna Bhattacharya, CEO - Nanoscope Therapeutics
    Eliana Merle
    Eliana Merle, Executive Director - USB
  8. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
    Breakout Session
    • Business Development and Investment
    Speakers
    Chad Wessel
    Chad Wessel, Director, Industry Analysis - Biotechnology Innovation Organization (BIO)
    Daniel Chancellor
    Daniel Chancellor, VP, Thought Leadership - Norstella
  9. Fireside Chat with Dr. Feng Zhang, Core Institute Member of the Broad Institute of MIT and Harvard, and Scientific Co-Founder of Moonwalk Biosciences
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Alex Aravanis
    Alex Aravanis, CEO & Founder - Moonwalk Biosciences
    Speakers
    Feng Zhang
    Feng Zhang, Feng Zhang is a core institute member of the Broad Institute of MIT and Harvard - Broad Institute of MIT
3:00 PM – 4:00 PM
(ET)
  1. The New Era of Project Optimus: Implications for Oncology Development Strategy
    Breakout Session
    • Oncology
    Moderator
    Andrew Zupnick
    Andrew Zupnick, VP, Oncology Drug Development - Catalyst Oncology
    Speakers
    Gilles Gallant
    Gilles Gallant, Chief Development Officer - Mythic Therapeutics, Inc.
    Keya Watkins
    Keya Watkins, Senior VP - Catalyst Oncology
  2. What are the Opportunities and Challenges for the New Generation of TechBio Partnerships Powered by Generative and Foundational AI?
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Brendan Frey
    Brendan Frey, Founder & Chief Innovation Officer - Deep Genomics
    Sergei Yakneen
    Sergei Yakneen, Chief Technology Officer - Isomorphic Labs
    Chris Hart
    Chris Hart
    Stacie Calad-Thomson
    Stacie Calad-Thomson, Business Development Lead, Healthcare and Life Sciences, North America - NVIDIA
  3. Expanding the Reach of Cell Therapies: Shaping the Future of Autoimmune Disease Treatment
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Kara Miller
    Kara Miller, Boston Globe Correspondent - Laurel Way Productions
    Speakers
    Carsten Brunn
    Carsten Brunn, CEO - Cartesian Therapeutics
    Rachel Haurwitz
    Rachel Haurwitz, CEO - Caribou Biosciences
    Joe Arron
    Joe Arron, Chief Scientific Officer - Sonoma Bio
    Richard Freed
    Richard Freed, CEO and Co-founder - RheumaGen
  4. Inflation Reduction Act (IRA) Litigation: Past and Future Impact on the Price Negotiation Framework
    Breakout Session
    • Intellectual Property and Legal Landscape
    Moderator
    John Delacourt
    John Delacourt, Deputy General Counsel, VP - Health, Regulatory & Commercial Operations - Biotechnology Innovation Organization (BIO)
    Speakers
    Julia Kiechel
    Julia Kiechel, VP, Commercial Litigation - Johnson & Johnson
    Chan Lee
    Chan Lee, General Counsel - BeiGene
  5. Overcoming Economic Challenges to Rare Disease Drug Development
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Patient Advocacy at Biotechnology Innovation Organization - Biotechnology Innovation Organization
    Speakers
    Camilla Graham
    Camilla Graham, Vice President Medical Affairs - PureTech Health
    Tamar Thompson
    Tamar Thompson, Head of Global Corporate Affairs, Alexion - Alexion Pharmaceuticals
    Christine Swenson
    Christine Swenson, Executive Regulatory Affairs Professional
  6. An Investor and a Value Assessor Walk into a Bar
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    Moderator
    Peter Kolchinsky
    Peter Kolchinsky, Managing Partner - RA Capital
    Speakers
    Melanie Whittington
    Melanie Whittington, Managing Director and Head - Leerink Center for Pharmacoeconomics
  7. Unlocking the Future: Opportunities and Challenges in Advanced Biologics Manufacturing
    Breakout Session
    • Biomanufacturing
    Moderator
    Ger Brophy
    Ger Brophy, Chair, Avantor Scientific Advisory Board - Avantor
    Speakers
    Stacy Springs
    Stacy Springs, Executive Director - MIT Center for Biomedical Innovation
    Johannes van der Loo
    Johannes van der Loo, Adjunct Associate Professor of Pathology and Laboratory Medicine - University of Pennsylvania's Perelman School of Medicine
  8. Fireside Chat with Dr. William Pao, author of "Breakthrough: The Quest for Life-Changing Medicines"
    Special Program
    Speakers
    William Pao
    William Pao
  9. Beyond the Deal: Navigating Increasingly Complex Collaborations in Pursuit of Innovation
    Breakout Session
    • Business Development and Investment
    Moderator
    Max Bayer
    Max Bayer, Pharma Reporter - Endpoints News
4:15 PM – 5:15 PM
(ET)
  1. Novel Oncology Targets & Modalities Enter the Clinic - What’s Next?
    Breakout Session
    • Oncology
    Moderator
    Selina Koch
    Selina Koch, Executive Editor, Head of Intelligence & Research - BioCentury Inc.
    Speakers
    William Sellers
    William Sellers, Core Institute Member and Cancer Program Director, Broad Institute - Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
    Angela Cacace
    Angela Cacace, Chief Scientific Officer - Arvinas
    Steven Bellon
    Steven Bellon, Chief Scientific Officer - Foghorn Therapeutics
  2. Flow of Capital to Women's Health: From Innovation to Patient
    Breakout Session
    • Business Development and Investment
    Moderator
    Misti Ushio
    Misti Ushio, Managing Partner - Digitalis Ventures
    Speakers
    Ipsita Smolinski
    Ipsita Smolinski, Founder & Managing Director - Capitol Street
    Rusty Ray
    Rusty Ray, Managing Partner - Alantra
    Meredith Fisher
    Meredith Fisher, Partner - Mass General Brigham Ventures
    Stacey Seltzer
    Stacey Seltzer, Managing Partner - Pontiva
    Megann Vaughn
    Megann Vaughn
  3. Policy Outlook: All Eyes on Intellectual Property Rights
    Breakout Session
    • Intellectual Property and Legal Landscape
    Moderator
    Sarah Alspach
    Sarah Alspach, Executive Vice President and Chief Communications Officer - Biotechnology Innovation Organization (BIO)
    Speakers
    Andrei Iancu
    Andrei Iancu, Co-founder and Board Chairman - Council for Innovation Promotion
    John Glasspool
    John Glasspool, CEO - VarmX
    Erika Smith
    Erika Smith, CEO - EpiTET Therapeutics
    Joseph Allen
    Joseph Allen, Executive Director - Bayh-Dole Coalition
  4. Co-Discovery and Co-Development Partnerships to Accelerate Next-Generation Medicines
    Breakout Session
    • Business Development and Investment
    Moderator
    Jake Beverage
    Jake Beverage, VP, Alliance Management - AbCellera
    Speakers
    Risa Shapiro
    Risa Shapiro, Head of Alliance Management for Platforms & Early R&D - Novartis
    Wanda Rutledge-Gordon
    Wanda Rutledge-Gordon, Associate Vice President, Chief Alliance Officer - Eli Lilly
    Peggy Scherle
    Peggy Scherle, Chief Scientific Officer - Prelude Therapeutics
    Jeremy Ahouse
    Jeremy Ahouse
  5. Bridging the Innovation Valley of Death: A Call for Greater Pharma-Biotech-Academia Collaboration
    Breakout Session
    • Translational Research
    Moderator
    Johannes Fruehauf
    Johannes Fruehauf, Founder and Chief Executive Officer - LabCentral / Biolabs
    Speakers
    Eric Kelsic
    Eric Kelsic, CEO & Cofounder - Dyno Therapeutics
    Andrew Mortlock
    Andrew Mortlock, EVP, Head of Early Development - Astellas Pharma Inc
    Angela Shen
    Angela Shen, Vice President, Strategic Innovation Leaders, Innovation; Head of Regulatory, Gene and Cell Therapy Institute - Mass General Brigham
  6. Innovative Patient-Focused Models for Accelerating Rare Drug Development
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    Cara Altimus
    Cara Altimus, Managing Director, Science Philanthropy Accelerator for Research and Collaboration - Milken Institute
    Speakers
    Sunitha Malepati
    Sunitha Malepati, Founder & CEO/VP - Buffalo Initiative/CACNA1A Foundation
    Nasha Fitter
    Nasha Fitter, Co-Founder & Chief Business Officer - Citizen Health
    Justin West
    Justin West, Co-Founder, President & Director of Clinical Medicine - KCNT1 Epilepsy Foundation
  7. Bridging the Biodata Gap: Revolutionizing AI's Impact in Biopharma by Creating ”Digital Twins” of the Natural World
    Breakout Session
    • AI and Digital Health
    Moderator
    Renee Yao
    Renee Yao, Ecosystem Business Development, Healthcare Life Sciences - NVIDIA
    Speakers
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Hannah England
    Hannah England, Partner - Ropes & Gray
    Patrick Schwab
    Patrick Schwab, Senior Director of Machine Learning and AI - GSK
    John Finn
    John Finn, Chief Scientific Officer - Basecamp Research
  8. Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: Four Industry-Academic Models
    Breakout Session
    • Diversity and Opportunity
    Moderator
    Maria Thacker Goethe
    Maria Thacker Goethe, President & CEO; Secretary & Board Member - Georgia Bio; Life Sciences Workforce Collaborative
    Speakers
    Jenae Williams
    Jenae Williams, Workforce and Partnerships Director of Workforce and Partnerships - NC Life Sciences Organization
    Angie McMurry
    Angie McMurry, Director, Industry Engagement and Workforce - Ohio Life Sciences
    Christopher Wild
    Christopher Wild, Assistant Vice Chancellor and Vice President - San Jacinto College
    John Newby
    John Newby, CEO - Virginia Biotechnology Association
  9. Next-Gen Medicine: How Gene Editing and Epigenetics are Revolutionizing Health, Longevity, and Organ Transplantation
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Uduak Thomas
    Uduak Thomas, Senior Editor - Genetic Engineering & Biotechnology News
    Speakers
    Elaine Cheung
    Elaine Cheung, Chief Business Officer - Moonwalk Biosciences
    Daniel Oliver
    Daniel Oliver, CEO and Co-founder - Rejuvenate Bio
    Wenning Qin
    Wenning Qin, SVP Innovation - eGenesis
    Jim Martineau
    Jim Martineau, CEO & Co-Founder - Nosis Bio
    Amber Salzman
    Amber Salzman, CEO - Epicrispr
  10. Book Signing with Dr. William Pao, author of "Breakthrough: The Quest for Life-Changing Medicines"
    Special Program
9:00 AM – 10:00 AM
(ET)
  1. Fueling Innovation: Strategies for Funding Academic Spin Outs
    Breakout Session
    • Translational Research
    Moderator
    Lisa Mueller
    Lisa Mueller, Ms - Casimir Jones
    Speakers
    Mike Partsch
    Mike Partsch, Chief Venture Officer - Wisconsin Alumni Research Foundation (WARF)
    Marc Sedam
    Marc Sedam, Vice President, Technology Opportunities & Ventures - NYU Langone Health
    Simon Warner
    Simon Warner, Head of Licencing and Ventures - Oxford University Innovation
    Nichole Mercier
    Nichole Mercier, Assistant Vice Chancellor and Managing Director (WashU); President and Co-Founder (Equalize Inc) - Washington University in St. Louis
  2. Trusting the Machines: Designing Transparent AI Solutions for Healthcare
    Breakout Session
    • AI and Digital Health
    Moderator
    Paul Howard
    Paul Howard, Executive Director, Policy and Patient Experience Innovation - Amicus Therapeutics
    Speakers
    Mida Pezeshkian
    Mida Pezeshkian, Founder, Principal - Stema-Cg
    Vangelis Vergetis
    Vangelis Vergetis, Co-founder - Epikast
    Erik Huestis
    Erik Huestis, Partner - Foley Hoag
    Michael Patriarca
    Michael Patriarca
  3. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
    Breakout Session
    • Business Development and Investment
    Speakers
    Donna LaVoie
    Donna LaVoie, Founder & CEO - LaVoieHealthScience
  4. Platform Power: How Genetic Medicine Technologies are Changing Expectations for Medicine
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Ryan Cross
    Ryan Cross, Senior Science Correspondent - Endpoints News
    Speakers
    Kevin Fitzgerald
    Kevin Fitzgerald, Chief Scientific Officer and Executive Vice President and Head of Research and Early Development - Alnylam Pharmaceuticals
    Laura Sepp-Lorenzino
    Laura Sepp-Lorenzino, Board Member, Scientific Advisor, and former Chief Scientific Officer - Intellia Therapeutics
    Christos Kyratsous
    Christos Kyratsous, Senior Vice President, Research and Co-Head, Regeneron Genetic Medicines - Regeneron
  5. The New Era of Mega Blockbusters: Advancing Drug Development for Broader Patient Impact
    Breakout Session
    • Business Development and Investment
    Moderator
    Jonathan Norris
    Jonathan Norris, Managing Director - HSBC Innovation
    Speakers
    Omar Khalil
    Omar Khalil, Managing Director - Santé Ventures
    Sarah Kilpatrick
    Sarah Kilpatrick, Vice President of Business Development for Pfizer R&D and Pfizer Internal Medicine - Pfizer
    Lizabeth Leveille
    Lizabeth Leveille, Vice President, BD&L - Merck
    Abbas Kazimi
    Abbas Kazimi, Chief Executive Officer - Nimbus Therapeutics
  6. Weight Loss for Longevity? How Metabolic Drugs are Disrupting Chronic Disease and Improving Healthspan
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Hilary Brueck
    Hilary Brueck, Health Correspondent - Business Insider
    Speakers
    Hanadie Yousef
    Hanadie Yousef, CEO and Co-Founder - Juvena Therapeutics
    Kristen Fortney
    Kristen Fortney, CEO and Co-Founder - BioAge Labs
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Maha Radhakrishnan
    Maha Radhakrishnan, Executive Partner, Private Equity - Sofinnova Investments
  7. In Pursuit of Health Equity: How Industry Has Evolved Its Focus On This Critical Healthcare Challenge
    Breakout Session
    • Diversity and Opportunity
    Moderator
    Chris Pernell
    Chris Pernell, Director, Center for Health Equity - NAACP
    Speakers
    Tanisha Sullivan
    Tanisha Sullivan, Head, External Engagement & Health Equity Strategy - Sanofi
  8. Delivering to the 80%: Scaling Community-Level CAR-T Access
    Breakout Session
    • Value‚ Patient Access and Reimbursement
10:15 AM – 11:15 AM
(ET)
  1. Copays Kill: How Cost Sharing Undermines Health
    Breakout Session
    • Patient Advocacy
    Speakers
    William Sarraille
    William Sarraille, Adjunct Professor - University of Maryland Francis King Carey School of Law
  2. Rescuing Promising but Shelved Assets: New Models to Overcome Barriers and Put Unmet Patient Needs First
    Breakout Session
    • Business Development and Investment
    Moderator
    Michael Gladstone
    Michael Gladstone, Partner - Atlas Venture
    Speakers
    Annette Bakker
    Annette Bakker, CEO - Children's Tumor Foundation
    Brent Kreider
    Brent Kreider, President - Biomed Valley Discoveries
    Uche Iloeje
    Uche Iloeje, Senior Vice President, and Head Global Medical Affairs - SpringWorks Therapeutics
    Samuel Blackman
    Samuel Blackman, Founder and Strategic Advisor - Day One Biopharmaceuticals
  3. Beyond Bispecifics and ADCs: Conditionally Active Biologics
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Michael Rice
    Michael Rice, Expert Advisor, SPV, Cell and Gene Therapy - Lumanity Inc.
    Speakers
    Neela Patel
    Neela Patel, Chief Business Officer - Bonum Therapeutics Inc.
    Stephen Demarest
    Stephen Demarest, Chief Scientific Officer - Tentarix Biotherapeutics Inc.
    Randi Isaacs
    Randi Isaacs, Chief Medical Officer - Werewolf Therapeutics Inc.
    Alexandra Cantley
    Alexandra Cantley, Partner - Polaris Partners
    Emmett Schmidt
    Emmett Schmidt, Vice President, Clinical Development - Merck
  4. Trends in Dealmaking: Shaping Drug Development Through External Innovation
    Breakout Session
    • Business Development and Investment
    Moderator
    Murray McCutcheon
    Murray McCutcheon, Senior Vice President, Partnering - AbCellera
    Speakers
    Lizabeth Leveille
    Lizabeth Leveille, Vice President, BD&L - Merck
    Michal Preminger
    Michal Preminger, Head, Johnson & Johnson Innovation, East North America - Johnson & Johnson
    Paul Thibodeau
    Paul Thibodeau
    Tomohiro Yamauchi
    Tomohiro Yamauchi, Executive Director, Global Head of Scouting & Transaction Oncology, Business Development - Astellas Pharma
  5. What If? Preparing for Cybersecurity Risks Begins by Understanding AI’s Role in Attacks and Defense
    Breakout Session
    • AI and Digital Health
    Moderator
    Lori Ellis
    Lori Ellis, Head of Insights - BioSpace
    Speakers
    Chris Hart
    Chris Hart, Partner - Foley Hoag
    Mike Walker
    Mike Walker, Executive Director, Global Healthcare and Life Sciences Digital Strategy - Microsoft
    Michael Elmore
    Michael Elmore, SVP & Global Chief Information Security Officer - GSK
    Matthew Hewitt
    Matthew Hewitt, Vice President, CTO Manufacturing Business Division - Charles River Laboratories
    Jay Ferro
    Jay Ferro, EVP, Chief Information, Technology, and Product Officer - Clario
  6. Revolutionizing Drug Development: Harnessing New Approach Methodologies (NAMs) for a Safer Future in Medicine
    Breakout Session
    • Translational Research
    Moderator
    Giulia Del Brenna
    Giulia Del Brenna, Head of Unit - Food, Retail, Health - European Commission
    Speakers
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Falk Ehmann
    Falk Ehmann, Head of Innovation and Development Accelerator - European Medicines Agency
    Gerd Kullak-Ublick
    Gerd Kullak-Ublick, Global Head, Mechanistic Safety and Safety Signal Management Patient Safety & Pharmacovigilance - Novartis
    Kylie Sproston
    Kylie Sproston, Chief Executive Officer - Bellberry Limited
  7. Reimbursement Innovation: Unlocking the Future of Advanced Therapy Access
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  8. Advancing Rare Disease: Strategic Innovations and Collaborative Efforts - Fireside Chat with Amy Comstock Rick, FDA Rare Disease Innovation Hub Director
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    E'Lissa Flores
    E'Lissa Flores, Director, Science and Regulatory Affairs - Biotechnology Innovation Organization (BIO)
    Speakers
    Amy Comstock Rick
    Amy Comstock Rick, Associate Director for Rare Disease Strategy, CDER - U.S. Food and Drug Administration
1:15 PM – 2:15 PM
(ET)
  1. 35th Biotech Beyond Borders Report: Are Capital Markets Finally Coming Back?
    Breakout Session
    • Business Development and Investment
    Moderator
    Arda Ural
    Arda Ural, Americas Life Sciences Sector Leader - EY-Parthenon
    Speakers
    Arda Ural
    Arda Ural, Americas Life Sciences Sector Leader - EY-Parthenon
    Paris Panayiotopoulos
    Paris Panayiotopoulos, Senior Managing Director - Blackstone Life Sciences Group
    Greg Verdine, PhD
    Greg Verdine, PhD, President, Chief Executive Officer, and Board Member - LifeMine Therapeutics
    Marian Nakada
    Marian Nakada, VP Venture Investments - Johnson & Johnson Innovation - JJDC
    Ryan MacDonald
    Ryan MacDonald
  2. Achieving Synergy: A Roadmap to Successful Academia-Industry Collaborations from Discussion to Implementation
    Breakout Session
    • Translational Research
    Moderator
    Ed Pagani
    Ed Pagani, Assistant Vice President for External Partnerships - Duke University Office for External Partnerships
    Speakers
    Caroline Lowenthal
    Caroline Lowenthal, Alliance Manager - MIT
    Tari Suprapto
    Tari Suprapto, Director for Search & Evaluation for Western US and Canada - Novo Nordisk
    Douglas Krafte
    Douglas Krafte, Chief Scientific Officer - Niroda Therapeutics
    Reed Sprague
    Reed Sprague, Executive Director, Stanford Medicine Industry Relations - Stanford Medicine
    Abubakar Jalloh
    Abubakar Jalloh, Associate Director, Corporate Development - Scripps Research
  3. The Role of Small Investors in the Biotech Funding Landscape – a Global Perspective
    Breakout Session
    • Business Development and Investment
    Speakers
    Yaniv Sneor
    Yaniv Sneor, Founder - Mid Atlantic Bio Angels
    Milla Koistinaho
    Milla Koistinaho, Founding Partner - Innovestor Life Science Fund
    Takehiko Sawabe
    Takehiko Sawabe, Director - Beyond Next Ventures
    Rob McInnes
    Rob McInnes, Lead, Life Sciences - Sydney Angels - Sydney Angels
  4. Celebrating Women Leading Innovation in Biopharma
    Breakout Session
    • Diversity and Opportunity
    Moderator
    Nicole DeFeudis
    Nicole DeFeudis, Editor - Endpoints News
    Speakers
    Judy Chou
    Judy Chou, President and CEO - AltruBio
    Sabrina Johnson
    Sabrina Johnson, President and CEO - Daré Bioscience
  5. Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    Marshall Summar
    Marshall Summar, CEO - Uncommon Cures
    Speakers
    Johann de Bruyn
    Johann de Bruyn, CEO
    Gareth Baynam
    Gareth Baynam
    Juan Francisco Cabello
    Juan Francisco Cabello
    Andrew McFadden
    Andrew McFadden
  6. Companies Should Embrace RWE Strategies Early and Often
    Breakout Session
    • AI and Digital Health
    Moderator
    Marnie Hoolahan
    Marnie Hoolahan, President - The NemetzGroup LLC
    Speakers
    Mei Sheng Duh
    Mei Sheng Duh, Managing Partner and Chief Epidemiologist, RPh, MPH, ScD - Analysis Group
    Ruth Pulikottil Jacob
    Ruth Pulikottil Jacob, EMEA HEOR Lead - Cepheid Danaher Company
    Raymond Mankoski
    Raymond Mankoski, Senior Medical Consultant - The NemetzGroup LLC
    Sara Silacci
    Sara Silacci, Founder and Managing Partner - Margin4Mission, LLC
  7. In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Daniel Getts
    Daniel Getts, Chief Executive Officer - Myeloid Therapeutics
    Speakers
    Kevin Friedman
    Kevin Friedman, Chief Executive Officer - Kelonia Therapeutics
    Geulah Livshits
    Geulah Livshits, Senior Research Analyst - Chardan
    Phil Johnson
    Phil Johnson, Chief Executive Officer - Interius BioTherapeutics
    Adrian Bot
    Adrian Bot, Chief Scientific Officer - Capstan Therapeutics
    David Fontana
    David Fontana, Chief Operating Officer - Umoja Biopharma
  8. Recognizing the Why Behind Our Medicines: Patient Connection as a Motivator for Impact
    Breakout Session
    • Patient Advocacy
    Moderator
    Michele Oshman
    Michele Oshman, Senior Vice President, External Affairs and Head, Patient Advocacy Center of Excellence - Biotechnology Innovation Organization
    Speakers
    Leslie Williams
    Leslie Williams, Co-Founder, President and CEO - HC Bioscience
    Sean Holleran
    Sean Holleran, Chief Executive Officer - Make-A-Wish Massachusetts and Rhode Island
    Samuel Blackman
    Samuel Blackman, Founder and Strategic Advisor - Day One Biopharmaceuticals
    Lianna Orlando
    Lianna Orlando, Vice President of Research and Partner, CureDuchenne Ventures - CureDuchenne
    Rich Brennan
    Rich Brennan, Vice President, Federal Affairs - The ALS Association
2:30 PM – 3:30 PM
(ET)
  1. Commercializing SBIR/STTR Technologies
    Breakout Session
    • Business Development and Investment
    Moderator
    Rupak Doshi
    Rupak Doshi, CEO - OmniSync Incorporated
    Speakers
    Fei Shen
    Fei Shen, Managing Director - Boehringer Ingelheim Venture Fund USA Inc.
    Prathamesh Prabhudesai
    Prathamesh Prabhudesai, CEO and Co-Founder - SafeBVM Corp.
    Evan Unger
    Evan Unger, Executive Chairman and Co-Founder - NuvOx Pharma
  2. US Legal and Regulatory Framework, Challenges, and Opportunities for AI Use in Pharma Product Development
    Breakout Session
    • Regulatory Innovation
    Moderator
    Xin Tao
    Xin Tao, Partner, Chair of U.S. Food and Drug Law Practice - Baker McKenzie
    Speakers
    Ben Rossen
    Ben Rossen, Associate General Counsel, AI Policy & Regulation - OpenAI
    Wentig Wang
    Wentig Wang, Global Head of Biomarker Statistics - Sanofi
    Victor Liang
    Victor Liang, Senior Director, Business Analytics and Strategic Advisory - Pi Health
  3. Optimizing Clinical Trial Design and Execution for Rare Diseases
    Breakout Session
    • Orphan and Rare Disease
    Moderator
    Marshall Summar
    Marshall Summar, CEO - Uncommon Cures
    Speakers
    Amy Comstock Rick
    Amy Comstock Rick, Associate Director for Rare Disease Strategy, CDER - U.S. Food and Drug Administration
    Janet Woodcock
    Janet Woodcock, Former Principal Acting Commissioner - FDA
    Emil Kakkis
    Emil Kakkis, President and CEO - Ultragenyx
  4. The “RNAissance” Era – Recent Breakthroughs, Future Prospects, and Challenges of RNA Therapeutics
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Jean Ge
    Jean Ge, Attorney, Biotechnology Practice - Wolf Greenfield
    Speakers
    Sacha Mann
    Sacha Mann, Experienced VC / Board Member / CEO / Company Builder - Stealth biotech
    Samir Ounzain
    Samir Ounzain, Chief Executive Officer & Scientific Co-Founder - HAYA Therapeutics
    Jill Goldstein
    Jill Goldstein, Principle - Vida Ventures
    Oxana Beskrovnaya
    Oxana Beskrovnaya, Chief Scientific Officer - Dyne Therapeutics
  5. We Still Need the People: AI/ML Drug Discovery is Here to Stay, but we Could be its Rate Limiting Factor
    Breakout Session
    • AI and Digital Health
    Moderator
    Alex Philippidis
    Alex Philippidis, Senior Business Editor - GEN
    Speakers
    Jennifer Chambers
    Jennifer Chambers, Senior Director of Education - Schrödinger
    Erin Davis
    Erin Davis, Chief Technology Officer - X-Chem
    Anna Marie Wagner
    Anna Marie Wagner, Founder/CEO - Stealth
    Wade Davis
    Wade Davis, Senior Vice President, Head of Digital for Business - Moderna
    Gurinder Singh “Mickey” Atwal
    Gurinder Singh “Mickey” Atwal, Chief Data and AI Officer, Pioneering Intelligence - Flagship Pioneering
  6. CI for the Biotech Journey: Applying Lessons from Pharma
    Breakout Session
    • Business Development and Investment
    Moderator
    Matthew Maryniak
    Matthew Maryniak, President - FENIX Group International LLC
    Speakers
    Benjamin Doran
    Benjamin Doran, Senior Vice President - Prescient Healthcare Group
    Justin Holko
    Justin Holko, Senior Vice President, Global Oncology & Hematology Business Unit - Regeneron
    Beth Vasievich
    Beth Vasievich, Head of Commercial Planning and Operations - CARGO Therapeutics
  7. How Massachusetts Built a Comprehensive Education and Workforce Development Continuum
    Breakout Session
    • Diversity and Opportunity
    Moderator
    Lauren Jones
    Lauren Jones, Secretary of Labor and Workforce Development - Commonwealth of Massachusetts
    Speakers
    Sunny Schwartz
    Sunny Schwartz, Chief Executive Officer - Massachusetts Biotechnology Education Foundation
    Emerson Foster
    Emerson Foster, Head of Human Resources, U.S. Business Unit - Takeda
    Monique Cooper
    Monique Cooper, Assistant Vice Provost for Academic and Career Engagement and Success - University of Massachusetts, Boston
    Rick Martel
    Rick Martel, Director, Downstream Manufacturing - Bristol Myers Squibb
    Debbie Durso-Bumpus
    Debbie Durso-Bumpus, Chief People Officer - Blueprint Medicines
  8. Closing the Practice Gaps in Precision Oncology – What are the Practical Solutions?
    Breakout Session
    • Diagnostics and Personalized Medicine
    Moderator
    Alasdair Milton
    Alasdair Milton, Principal, Precision Medicine Leader, Healthcare and Life Sciences Strategy - KPMG LLP
    Speakers
    Gabriele Allegri
    Gabriele Allegri, Commercial Head, Precision Medicine - Johnson and Johnson Innovative Medicine
    Terri Conneran
    Terri Conneran, Cancer Survivor & Founder - KRAS Cancer Connect | KRAS Kickers
    Lecia Sequist
    Lecia Sequist, Medical Oncologist and Program Director, Cancer Early Detection and Diagnostics Clinic - Massachusetts General Hospital
    Daryl Pritchard
    Daryl Pritchard, Senior Vice President, Science Policy - Personalized Medicine Coalition
    Maria Karasarides
    Maria Karasarides, Board Member - From Testing to Targeted Treatment (FT3)
9:00 AM – 10:00 AM
(ET)
  1. Biotech M&A 2025: What’s Driving Deal-Making in The New Environment
    Breakout Session
    • Business Development and Investment
    Moderator
    Matthew Gardella
    Matthew Gardella, Member - Mintz
    Speakers
    Agnieszka (Aggie) Gallagher
    Agnieszka (Aggie) Gallagher, Senior Vice President and Chief Legal Officer - Standard BioTools Inc.
    Andrew Rymer
    Andrew Rymer, Partner - Centerview Partners LLC
    William Fiske
    William Fiske, Head of M&A and Contested Situations – U.S. - Georgeson LLC
    Dan Moore
    Dan Moore, Founding Partner - Collected Strategies
  2. Accelerated Approval and Patient Need: The Value of Earlier Access
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    Moderator
    John O'Brien
    John O'Brien, President and CEO - National Pharmaceutical Council
    Speakers
    Jeff Allen
    Jeff Allen, President and CEO - Friends of Cancer Research
    Annie Kennedy
    Annie Kennedy, Chief of Policy, Advocacy and Patient Engagement - EveryLife Foundation for Rare Diseases
    Sue Peschin
    Sue Peschin, President and CEO - Alliance for Aging Research
    Silas Martin
    Silas Martin, Head, Access and Policy Research - Johnson & Johnson
  3. An Eye on I&I: Innovations Fueling Growth
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Allison deAngelis
    Allison deAngelis, Biotech Startups and Venture Capital Reporter Biotech Startups and Venture Capital Reporter Biotech Startups and Venture Capital Reporter - STAT News
    Speakers
    Judy Chou
    Judy Chou, President and CEO - AltruBio
    Kari Brown
    Kari Brown, Chief Medical Officer - Revolo Biotherapeutics
    Dan Passeri
    Dan Passeri, Chief Executive Officer - Cue Biopharma
    Jose Terencio
    Jose Terencio, Senior Vice President, Discovery - Grifols
    Frank Nestle
    Frank Nestle, Partner and CEO of 3DC - Deerfield Management
  4. Expediting Impact: Leveraging the Patient Voice for Enhanced Clinical Trial Design and Accelerated Regulatory Approvals
    Breakout Session
    • Regulatory Innovation
    Moderator
    Noah Siedman
    Noah Siedman, Community & Database Manager - BDSRA Foundation
    Speakers
    Richard Wilson
    Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation - Astellas
    Kiran Nistala
    Kiran Nistala, Chief Medical Officer and Head of Development - Zura Bio
    Darren Johnson
    Darren Johnson, Medical Science Liaison - Vor Bio
  5. Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery
    Breakout Session
    • AI and Digital Health
    Moderator
    Alex Knapp
    Alex Knapp, Senior Editor - Forbes
    Speakers
    Andrei Georgescu
    Andrei Georgescu, CEO & Founder - Vivodyne
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Wyatt McDonnell
    Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Cheng Zhang
    Cheng Zhang, CEO & Founder - Character Bio
    Carlos Bustamante
    Carlos Bustamante, CEO & Co-Founder - Galatea Bio
  6. The Landscape for Cell Therapy and Gene Therapy – Challenges and Opportunities from Drug Development to Patient Access
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    Moderator
    Phyllis Arthur
    Phyllis Arthur, Executive Vice President & Head of Healthcare Policy and Programs - Biotechnology Innovation Organization (BIO)
    Speakers
    Jayson Slotnik
    Jayson Slotnik, Principal - Health Policy Strategies
10:15 AM – 11:15 AM
(ET)
  1. The Innovation Race vs. Regulatory Pace: What to Do When Innovation Outpaces Regulation
    Breakout Session
    • Regulatory Innovation
    Moderator
    Angela Specht
    Angela Specht, Global Head, BARDA Alliance - Johnson & Johnson
    Speakers
    Adora Ndu
    Adora Ndu, Chief Regulatory Officer, and Executive Vice President of Portfolio Strategy and Management - BridgeBio Pharma, Inc.
    Jeremiah Kelly
    Jeremiah Kelly, Partner - Veneble LLP
    Paul Kim
    Paul Kim, Principal - Kendall Square Policy Strategies, LLC
    Cory Sago
    Cory Sago, CEO - Amplitude Therapeutics
  2. Weighing in on Weight Loss Medicine
    Breakout Session
    • Next Generation Biotherapeutics
    Moderator
    Jonah Comstock
    Jonah Comstock, Editor in Chief - pharmaphorum
    Speakers
    Steffen-Sebastian Bolz
    Steffen-Sebastian Bolz, Co-Founder & Chief Scientific Officer - Aphaia Pharma
    Punit Dhillon
    Punit Dhillon, Chief Executive Officer - Skye Bioscience
    Beverly Tchang
    Beverly Tchang, Assistant Professor of Clinical Medicine - Weill Cornell
    Dave Knapp
    Dave Knapp, Patient Advocate; Host - On The Pen
  3. Carving Out Your Ground in Immunology & Inflammation (I&I)
    Breakout Session
    • Business Development and Investment
    Moderator
    Mark Dowling
    Mark Dowling, Head of Search & Evaluation - Immunology - Sanofi Genzyme
    Speakers
    Bruce Jacobs
    Bruce Jacobs, Chief Financial Officer - Kymera
    Dan Koerwer
    Dan Koerwer, Chief Operating Officer - Ventus Therapeutics
    Kathy Dong
    Kathy Dong, President and Chief Executive Officer - Electra Therapeutics
    John Sundy
    John Sundy, Chief Medical Officer - Seismic Therapeutic
  4. Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
    Breakout Session
    • AI and Digital Health
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Kfir Schreiber
    Kfir Schreiber, CEO & Co-Founder - DeepCure
    Anne Carpenter
    Anne Carpenter, Institute Scientist - Broad Institute (SAB: SyzOnc, Recursion, Quiver)
    Michelle Chen
    Michelle Chen, Chief Business Officer - Insilico Medicine
    Matt Truppo
    Matt Truppo, Global Head of Research Platforms and Computational R&D - Sanofi
  5. Physician and Patient Perspectives on the Impact of the Inflation Reduction Act on Drug Development, Access, and Innovation
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    Moderator
    Steven Potts
    Steven Potts, Chairman - Breakthru Bio
    Speakers
    Barbara McAneny
    Barbara McAneny, Former President AMA ; CEO- NM Oncology Hematology Consultants Ltd, ONCare Alliance Co-Chair - New Mexico Oncology Hematology Consultants, Ltd.
  6. A New Era in Organ Transplantation: Advancing Xenotransplantation with Genetic Engineering
    Breakout Session
    • Business Development and Investment
    Speakers
    Mike Curtis
    Mike Curtis, CEO - eGenesis
    Leonardo Riella
    Leonardo Riella, Harold and Ellen Danser Endowed Chair in Transplantation and Associate Professor of Medicine - Massachusetts General Hospital, Harvard Medical School
    David-Alexandre Agros
    David-Alexandre Agros, CEO - Eledon

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS

Loading

Search
Sharpen your BD skills

Sharpen your BD skills

Take a 1-3 day course before BIO 2025 for intense training in our Professional Development Courses.

Learn more